(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

AS PHARMA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

AS PHARMA

ST13

US500000097562350

Class

35, 42, 43, 45

Filing

97562350

Registration

7192970

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

20

Latest update

10/17/2023

Trademark type

Combined

Nice classes

35, 42, 43, 45

Filing date

08/24/2022

Registration date

10/17/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

10/17/2023

Last transaction

10/17/2023

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

First use anywhere

08/15/2022

First use in commerce

08/15/2022

Drawing code

3

Owner type

16

Owner location

Wilmington, DE, US

Examiner

TRUSILO, KELLY

Law office

L70

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the letters "AS" in dark green surrounded by light green and green semi-circles with the word "PHARMA" in purple within a green semi-circle below the letter "A". The color white consists of background shading and is not claimed as part of the mark.

Holders and representatives

Holders

AS Pharma Consulting, LLC

Representatives

Kurt D. Olender OLENDERFELDMAN LLP

Technical classification

Nice Classes

Class 35Class 42Class 43Class 45

Vienna Codes

No Vienna codes available.

Goods and services

Class 35

Business consulting services for pharmaceuticallife sciencebiotech businesses in the nature of regulatory submission managementassisting others in filing applications for new pharmaceuticals with governmental regulatory bodies

Class 42

Providing scientific consulting services to support the research and development of pharmaceuticals and other healthcare related products for pharmaceuticallife sciencebiotech businesses

Class 43

Providing clinical medical consulting services to support the research and development of pharmaceuticals and other healthcare related products for pharmaceuticallife sciencebiotech businesses

Class 45

Providing regulatory compliance consulting services in the field of pharmaceuticals and other healthcare related products for pharmaceuticallife sciencebiotech businesses

Publications

History of USPTO decisions and trademark events.

20 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

10/17/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

10/17/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

08/01/2023

PUBO

PUBLISHED FOR OPPOSITION

08/01/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/12/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/26/2023

XAEC

EXAMINER'S AMENDMENT ENTERED

06/26/2023

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

06/26/2023

GNEA

EXAMINERS AMENDMENT E-MAILED

06/26/2023

CNEA

EXAMINERS AMENDMENT -WRITTEN

06/26/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/20/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/19/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

06/19/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

06/12/2023

GNRT

NON-FINAL ACTION E-MAILED

06/12/2023

CNRT

NON-FINAL ACTION WRITTEN

06/12/2023

DOCK

ASSIGNED TO EXAMINER

06/11/2023

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

09/14/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/13/2022

NWAP

NEW APPLICATION ENTERED

08/27/2022

Continuous trademark protection

Get notified about every new filing that threatens AS PHARMA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.